Track topics on Twitter Track topics that are important to you
SCOTTSDALE, AZ--(Marketwired - August 04, 2016) - NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES
Lattice Biologics Ltd.
(TSX VENTURE: LBL) (OTCBB: BLVKF) (the "Company") announced today 7 new biologic products as part of our ongoing commitment to deliver the highest quality innovative regenerative medicine solutions. These products have been developed by our Research and Development team in concert with valuable feedback from Lattice Biologics' Scientific Advisory Board (SAB) members and surgeon partners.
These novel allografts reflect the Company's continued efforts to refine and expand its product offering to meet the industry's changing needs with advanced technology. Through the highest processing methods and modern solutions to today's surgical challenges, these products embody the Company's mission "to honor the gift of tissue donation by adhering to the highest standards in safety, service, and quality."
"This is a
great product. We are very satisfied with its performance."
-- Plastic Surgeon in Pittsburgh, PA in regards to using new Lattice Biologics products.
"We are very proud of our development team and their extremely fast turnaround time for these new products, which represent surgeon feedback based on countless hours in the operating room, managing some of the most complex cases,"
commented CEO, Guy Cook. "They have been developed to be responsive to the unique challenges of common indications and deliver improved results."
"The unique shapes and sizing of these products," continued Cook, "helps speed the surgery process, which reduces the amount of time patients are under anesthesia and the potential for complications. Our R&D team has also improved the handling properties of several allografts to achieve a new industry standard in response to surgeon requests."
"The ADM graft for (the doctor) was received in a positive manner. He liked the feel of the graft and mentioned that it performed very well!"
-- Surgical Assistant -- Chicago, IL
"Everything went great… they worked really well and I liked using them. I think they were more pliable than Alloderm."
-- Plastic Surgeon -- Atlanta, GA
Lattice Biologics Ltd.
Guy Cook,Chief Executive OfficerTelephone No: (480) 563-0800
About Lattice Biologics Ltd.:
Lattice Biologics recently completed its RTO, becoming a publically traded company on January 4, 2016 and is traded on the TSX-V under the symbol: LBL. The Company is an emerging personalized/precision medicine leader in the field of cellular therapies and tissue engineering, with a focus on bone, skin, and cartilage regeneration. Lattice Biologics develops and manufactures biologic products to domestic and international markets. Lattice's products are used in a variety of surgical applications.
Lattice Biologics maintains its headquarters, laboratory and manufacturing facilities in Scottsdale, Arizona as well as offices in Toronto Ontario. The facility includes ISO Class 1000 and ISO Class 100 clean rooms, and specialized equipment capable of crafting traditional allografts and precision specialty allografts for various clinical applications. The Lattice Biologics team includes highly trained tissue bank specialists, surgical technicians, certified sterile processing and distribution technicians, and CNC operators who maintain the highest standards of aseptic technique throughout each step of the manufacturing process. From donor acceptance to the final packaging and distribution of finished allografts, Lattice is committed to maintaining the highest standards of allograft quality, innovation, and customer satisfaction.
Lattice Biologics maintains all necessary licensures to process and sell its tissue engineered products within the U.S. and internationally. This includes Certificates to Foreign Governments from the U.S. Food and Drug Administration (FDA) and registrations for 29 countries, which allow the export of bone, tendon, meniscus, ligament, soft tissue, and cartilage products outside of the U.S.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement on Forward-Looking Information:
Certain information contained in this news release constitutes "forward-looking statements" within the meaning of the 'safe harbour' provisions of Canadian securities laws. All statements herein, other than statements of historical fact, are to be considered forward-looking. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "potential", "future", "expected", "could", "possible", "goal", "intends", "will" or similar expressions identify forward-looking statements. Forward-looking statements in this news release include, without limitation: information pertaining to the Company's strategy, plans, or future financial performance, such as statements with respect to future sales or revenues, expected outcomes with respect to the Company's research studies, and other statements that express management's expectations or estimates of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Lattice to be materially different from those expressed or implied by such forward-looking statements.
Forward-looking statements are necessarily based upon a number of factors and assumptions that, while considered reasonable by management as of the date such statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies. The factors and assumptions that could prove to be incorrect, include, but are not limited to: that market prices will be consistent with expectations, the continued availability of capital and financing, and that general economic, market and business conditions will be consistent with expectations. The forward-looking statements are not guarantees of future performance. We disclaim any obligation to update or revise any forward-looking statements, except as required by law. Readers are cautioned not to put undue reliance on these forward-looking statements.
United States Advisory: The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered, sold, or resold in the United States or to, or for the account of or benefit of, a U.S. Person (as such term is defined in Regulation S under the U.S. Securities Act) unless an exemption from the registration requirements of the U.S. Securities Act is available. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in the state in the United States in which such offer, solicitation or sale would be unlawful.
Follow us on Twitter:
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...